Martine Escoffre

Rennes, FR 
Rennes, FR 

Overview

Martine Escoffre practices practicing medicine in Rennes, France.

Her clinical expertise encompasses Multiple Myeloma, Chronic Myelogenous Leukemia (CML), Leukemia, and Acute Lymphoblastic Leukemia (ALL).

She is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Rennes, France
Other Locations
Caen, France
Marseille, France
Hôpital St. Louis, Hôpital St. Antoine, Lille And Hôtel Dieu, Nantes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Enrollment Status: Completed
Publish Date: November 24, 2025
Intervention Type: Procedure, Drug
Study Drug: Pomalidomide+Cyclophosphamide+Dexamethasone
Study Phase: Phase 2
Randomized Phase II Study Evaluating the Efficacy of 90Yttrium-epratuzumab Tetraxetan Radioimmunotherapy in Adults With CD22+ Relapsed/Refractory B-ALL
Randomized Phase II Study Evaluating the Efficacy of 90Yttrium-epratuzumab Tetraxetan Radioimmunotherapy in Adults With CD22+ Relapsed/Refractory B-ALL
Enrollment Status: Withdrawn
Publish Date: January 19, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

13 Total Publications

Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST Study.
Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST Study.
Journal: Blood
Published: January 20, 2026

Frequently Asked Questions about Martine Escoffre

Is Martine Escoffre a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Martine Escoffre is classified as an Experienced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Martine Escoffre participate in research or clinical trials?

Yes. Martine Escoffre has published 13 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Martine Escoffre's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Escoffre's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile